Evotec (EVO) Competitors

$2.72 +0.01 (+0.37%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$2.72 +0.00 (+0.18%)

As of 05/14/2026 04:57 PM Eastern

EVO vs. LEGN, KNSA, NNNN, CRNX, and TVTX

Should you buy Evotec stock or one of its competitors? MarketBeat compares Evotec with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evotec include Legend Biotech (LEGN), Kiniksa Pharmaceuticals International (KNSA), Anbio Biotechnology (NNNN), Crinetics Pharmaceuticals (CRNX), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

How does Evotec compare to Legend Biotech?

Evotec (NASDAQ:EVO) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Legend Biotech has a net margin of -21.98% compared to Evotec's net margin of -26.20%. Legend Biotech's return on equity of -24.92% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Legend Biotech	-21.98%	-24.92%	-14.87%

Evotec presently has a consensus target price of $7.00, indicating a potential upside of 157.35%. Legend Biotech has a consensus target price of $59.00, indicating a potential upside of 106.29%. Given Evotec's higher possible upside, equities analysts clearly believe Evotec is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evotec has higher earnings, but lower revenue than Legend Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.08	-$117.12M	N/A	N/A
Legend Biotech	$1.14B	4.64	-$296.80M	-$0.68	N/A

5.8% of Evotec shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 1.0% of Evotec shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Evotec has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

In the previous week, Evotec had 6 more articles in the media than Legend Biotech. MarketBeat recorded 18 mentions for Evotec and 12 mentions for Legend Biotech. Evotec's average media sentiment score of 0.42 beat Legend Biotech's score of -0.36 indicating that Evotec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Evotec and Legend Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Evotec compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Evotec's net margin of -26.20%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Evotec	-26.20%	-24.93%	-11.35%

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	6.65	$59.01M	$0.90	65.04
Evotec	$891.97M	1.08	-$117.12M	N/A	N/A

Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Evotec has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus target price of $60.86, indicating a potential upside of 3.96%. Evotec has a consensus target price of $7.00, indicating a potential upside of 157.35%. Given Evotec's higher probable upside, analysts clearly believe Evotec is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Evotec had 14 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 18 mentions for Evotec and 4 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Evotec's score of 0.42 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Evotec on 10 of the 14 factors compared between the two stocks.

How does Evotec compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Evotec (NASDAQ:EVO) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

5.8% of Evotec shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has a beta of 4.71, indicating that its share price is 371% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Anbio Biotechnology's return on equity of 0.00% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Evotec	-26.20%	-24.93%	-11.35%

Anbio Biotechnology has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	417.03	$6.40M	N/A	N/A
Evotec	$891.97M	1.08	-$117.12M	N/A	N/A

In the previous week, Evotec had 17 more articles in the media than Anbio Biotechnology. MarketBeat recorded 18 mentions for Evotec and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Evotec's score of 0.42 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Evotec	Neutral

Evotec has a consensus target price of $7.00, indicating a potential upside of 157.35%. Given Evotec's stronger consensus rating and higher probable upside, analysts clearly believe Evotec is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Anbio Biotechnology and Evotec tied by winning 7 of the 14 factors compared between the two stocks.

How does Evotec compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Evotec has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

Evotec has a net margin of -26.20% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Evotec's return on equity of -24.93% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Evotec	-26.20%	-24.93%	-11.35%

Evotec has higher revenue and earnings than Crinetics Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	524.60	-$465.32M	-$5.13	N/A
Evotec	$891.97M	1.08	-$117.12M	N/A	N/A

In the previous week, Crinetics Pharmaceuticals had 14 more articles in the media than Evotec. MarketBeat recorded 32 mentions for Crinetics Pharmaceuticals and 18 mentions for Evotec. Evotec's average media sentiment score of 0.42 beat Crinetics Pharmaceuticals' score of -0.04 indicating that Evotec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Evotec	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crinetics Pharmaceuticals currently has a consensus target price of $76.13, indicating a potential upside of 98.71%. Evotec has a consensus target price of $7.00, indicating a potential upside of 157.35%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Evotec beats Crinetics Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Evotec compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Travere Therapeutics has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	8.36	-$25.55M	-$0.23	N/A
Evotec	$891.97M	1.08	-$117.12M	N/A	N/A

Travere Therapeutics has a net margin of -4.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Evotec	-26.20%	-24.93%	-11.35%

5.8% of Evotec shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Travere Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

In the previous week, Evotec had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 18 mentions for Evotec and 15 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.76 beat Evotec's score of 0.42 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Travere Therapeutics currently has a consensus target price of $47.83, indicating a potential upside of 8.47%. Evotec has a consensus target price of $7.00, indicating a potential upside of 157.35%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Travere Therapeutics beats Evotec on 8 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$965.16M	$3.06B	$6.34B	$12.37B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	N/A	18.70	20.66	25.63
Price / Sales	1.08	271.92	545.73	76.59
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	1.18	4.42	9.94	6.97
Net Income	-$117.12M	$72.19M	$3.55B	$333.62M
7 Day Performance	-11.40%	-0.43%	1.70%	1.09%
1 Month Performance	-15.26%	-0.96%	0.49%	3.08%
1 Year Performance	-30.96%	45.81%	39.38%	35.68%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	3.1841 of 5 stars	$2.72 +0.4%	$7.00 +157.4%	-33.3%	$965.16M	$891.97M	N/A	4,553	Short Interest Decrease Gap Up
LEGN Legend Biotech	3.9204 of 5 stars	$26.50 +12.3%	$58.31 +120.0%	+2.9%	$4.36B	$1.03B	N/A	2,965	Earnings Report Analyst Forecast
KNSA Kiniksa Pharmaceuticals International	3.4286 of 5 stars	$57.62 +4.3%	$60.86 +5.6%	+133.9%	$4.23B	$677.56M	64.02	220	Positive News
NNNN Anbio Biotechnology	0.9258 of 5 stars	$29.98 +3.7%	N/A	N/A	$4.16B	$8.65M	N/A	27	Positive News
CRNX Crinetics Pharmaceuticals	2.0547 of 5 stars	$41.25 +5.7%	$76.75 +86.1%	+22.4%	$4.11B	$7.70M	N/A	210	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors

EVO vs. LEGN, KNSA, NNNN, CRNX, and TVTX

How does Evotec compare to Legend Biotech?

Summary

How does Evotec compare to Kiniksa Pharmaceuticals International?

Summary

How does Evotec compare to Anbio Biotechnology?

Summary

How does Evotec compare to Crinetics Pharmaceuticals?

Summary

How does Evotec compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evotec (EVO) Competitors

EVO vs. LEGN, KNSA, NNNN, CRNX, and TVTX

How does Evotec compare to Legend Biotech?

Is EVO or LEGN more profitable?

Do analysts rate EVO or LEGN?

Which has better earnings and valuation, EVO or LEGN?

Do institutionals and insiders believe in EVO or LEGN?

Which has more volatility & risk, EVO or LEGN?

Does the media favor EVO or LEGN?

Summary

How does Evotec compare to Kiniksa Pharmaceuticals International?

Is KNSA or EVO more profitable?

Which has higher valuation & earnings, KNSA or EVO?

Which has more volatility & risk, KNSA or EVO?

Do analysts prefer KNSA or EVO?

Does the media prefer KNSA or EVO?

Do institutionals & insiders believe in KNSA or EVO?

Summary

How does Evotec compare to Anbio Biotechnology?

Do institutionals & insiders believe in NNNN or EVO?

Which has more volatility & risk, NNNN or EVO?

Is NNNN or EVO more profitable?

Which has higher valuation & earnings, NNNN or EVO?

Does the media prefer NNNN or EVO?

Do analysts prefer NNNN or EVO?

Summary

How does Evotec compare to Crinetics Pharmaceuticals?

Do insiders and institutionals believe in CRNX or EVO?

Which has more volatility and risk, CRNX or EVO?

Is CRNX or EVO more profitable?

Which has better valuation and earnings, CRNX or EVO?

Does the media prefer CRNX or EVO?

Do analysts prefer CRNX or EVO?

Summary

How does Evotec compare to Travere Therapeutics?

Which has better valuation and earnings, TVTX or EVO?

Is TVTX or EVO more profitable?

Do insiders and institutionals believe in TVTX or EVO?

Which has more volatility and risk, TVTX or EVO?

Does the media prefer TVTX or EVO?

Do analysts prefer TVTX or EVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools